Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with moderate and severe traumatic brain injury

Neurology India

Volumn 61, Issue 6, 2013, Pages 606-609

  Zheng, Kebin ^a   Li, Chunhui ^a   Shan, Xiaosong ^a   Liu, Haipeng ^a   Fan, Wufang ^a   Wang, Zhenshan ^a   Zheng, Ping ^b  

^a HEBEI UNIVERSITY   (China)

^b Shanghai Pudong New Area People s Hospital   (China)

Author keywords

Cerebrospinal fluid; matrix metalloproteinase; tissue inhibitor of metalloproteinase; traumatic brain injury

Indexed keywords

BRAIN INJURIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; ROC CURVE; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84894221145     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.125258     Document Type: Article

References (24)

1. Bruns J Jr, Hauser WA. The epidemiology of traumatic brain injury: A review. Epilepsia 2003;44:2-10.
2. Langlois JA, Rutland-Brown W, Wald MM. The epidemiology and impact of traumatic brain injury: A brief overview. J Head Trauma Rehabil 2006;21:375-8.
3. Jiang JY. Collaborators CHTS. Head trauma in China. Injury 2012; In press.
4. Begaz T, Kyriacou DN, Segal J, Bazarian JJ. Serum biochemical markers for post-concussion syndrome in patients with mild traumatic brain injury. J Neurotrauma 2006;23:1201-10.
5. Kochanek PM, Berger R P, Bayir H, Wagner AK, Jenkins LW, Clark RS. Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: Diagnosis, prognosis, probing mechanisms, and therapeutic decision making. Curr Opin Crit Care 2008;14:135-41.
6. Azeh I, Mäder M, Smirnov A, Beuche W, Nau R, Weber F. Experimental pneumococcal meningitis in rabbits: The increase of matrix metalloproteinase-9 in cerebrospinal fluid correlates with leucocyte invasion. Neurosci Lett 1998;256:127-30.
7. Khrestchatisky M, Jourquin J, Ogier C, Charton G, Bernard A, Tremblay E, et al. Matrix metalloproteinases and their inhibitors, modulators of neuro-immune interactions and of pathophysiological processes in the nervous system. J Soc Biol 2003;197:133-44.
8. Kanoh Y, Ohara T, Kanoh M, Akahoshi T. Serum matrix metalloproteinase-2 levels indicate blood-CSF barrier damage in patients with infectious meningitis. Inflammation 2008;31:99-104.
9. Rosenberg GA, Navratil M, Barone F, Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996;16:360-6.
10. Gasche Y, Fujimura M, Morita-Fujimura Y, Copin JC, Kawase M, Massengale J, et al. Early appearance of activated matrix metalloproteinase-9 after focal cerebral ischemia in mice: A possible role in blood-brain barrier dysfunction. J Cereb Blood Flow Metab 1999;19:1020-8.
11. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999;19:624-33.
12. Lin Y, Pan Y, Wang M, Huang X, Yin Y, Wang Y, et al. Blood-brain barrier permeability is positively correlated with cerebral microvascular perfusion in the early fluid percussion-injured brain of the rat. Lab Invest 2012;92:1623-34.
13. Wang X, Jung J, Asahi M, Chwang W, Russo L, Moskowitz MA, et al. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 2000;20:7037-42.
14. Wang X, Mori T, Jung JC, Fini ME, Lo EH. Secretion of matrix metalloproteinase-2 and-9 after mechanical trauma injury in rat cortical cultures and involvement of MAP kinase. J Neurotrauma 2002;19:615-25.
15. Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery 2009;65:702-8.
16. Johanson M, Zhao XR, Huynh-Ba G, Villar CC. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases, and inflammation in cyclosporine A-induced gingival enlargement: A pilot in vitro study using a three-dimensional model of the human oral mucosa. J Periodontol 2013;84:634-40.
17. Wang JJ, Huan SK, Hsieh KH, Chou HC, Hsiao G, Jayakumar T, et al. Inhibitory effect of midazolam on MMP-9, MMP-1 and MMP-13 expression in PMA-stimulated human chondrocytes via recovery of NF-kB signaling. Arch Med Sci 2013;9:332-9.
18. Kavalci C, Genchallac H, Durukan P, Cevik Y Value of biomarker-based diagnostic test in differential diagnosis of hemorrhagic-ischemic stroke. Bratisl Lek Listy 2011;112:398-401.
19. Niebroj-Dobosz I, Janik P, Sokolowska B, Kwiecinski H. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur J Neurol 2010;17:226-31.
20. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-96.
21. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003;92:827-39.
22. Lorenzl S, Albers DS, LeWtt PA, Chirichigno JW, Hilgenberg SL, Cudkowicz ME, et al. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 2003;207:71-6.
23. Renaud S, Leppert D. Matrix metalloproteinases in neuromuscular disease. Muscle Nerve 2007;36:1-13.
24. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009;8:205-16.